T790M-positive | CancerGRACE

Divergent Paths for Tagrisso (Osimertinib) and Rociletinib for EGFR T790M Mutation-Positive NSCLC and Acquired Resistance: What Happened, and Where Are We Now?

Article

Read more about Divergent Paths for Tagrisso (Osimertinib) and Rociletinib for EGFR T790M Mutation-Positive NSCLC and Acquired Resistance: What Happened, and Where Are We Now?
14 comments

Emerging Options for T790M-Positive Acquired Resistance

Video

Acquired resistance in EGFR patients is often driven by the T790M mutation. T790M-positive tumors respond differently to treatments than T790M-negative tumors. Dr. Greg Riely details how each status can predict patients' responses to current treatments.

Read more about Emerging Options for T790M-Positive Acquired Resistance

Subscribe to T790M-positive

Log in
FIGHT
EDUCATE
PARTICIPATE
- Community Forum
- Get Involved
  - Memorials and Tributes
  - Volunteer Opportunities
ABOUT CancerGRACE
DONATE
- Why Give to GRACE